目的:本研究旨在探讨妥布他丁-A的治疗效果,糖皮质激素受体(GR)线粒体易位抑制剂,和米托醌(MitoQ),抗氧化剂,减轻地塞米松(DEX)诱导的巨噬细胞凋亡。方法:我们用DEX和Tubastatin-A或MitoQ的不同组合处理RAW264.7巨噬细胞。参数,如线粒体GR易位,线粒体活性氧水平,线粒体膜电位,线粒体通透性过渡孔开放,细胞色素C流出到细胞质,随后通过qRT-PCR在不同的治疗组中评估细胞凋亡,西方印迹,和免疫荧光分析。结果:DEX干预增加了GRs向线粒体的易位,同时降低线粒体基因MT-CO1的表达和巨噬细胞中线粒体呼吸链复合物IV的活性。此外,DEX给药增加了mtROS水平,线粒体通透性过渡孔开放,和线粒体细胞色素C在巨噬细胞中的释放,这促进了它们的凋亡。我们发现Tubastatin-A抑制线粒体GR易位并逆转DEX诱导的线粒体内GR水平的增加。此外,Tubastatin-A减轻了DEX诱导的各种线粒体变化,包括减少线粒体细胞色素C的外排和抑制巨噬细胞凋亡。同样,MitoQ通过线粒体途径降低mtROS水平对巨噬细胞凋亡产生影响。结论:DEX介导的GR易位进入线粒体破坏了巨噬细胞的线粒体功能,诱导它们的凋亡。通过抑制GR的线粒体易位和降低mtROS水平,Tubastatin-A和MitoQ能有效抑制巨噬细胞凋亡,这对减少与糖皮质激素使用相关的显著副作用具有临床意义。
UNASSIGNED: Our research aimed to investigate the therapeutic effects of Tubastatin-A, a glucocorticoid receptor (GR) mitochondrial translocation inhibitor, and mitoquinone (MitoQ), an antioxidant, on attenuating dexamethasone (DEX)-induced macrophage apoptosis.
UNASSIGNED: We treated RAW264.7 macrophages with different combinations of DEX and either Tubastatin-A or MitoQ. Parameters such as mitochondrial GR translocation, mitochondrial reactive oxygen species levels, mitochondrial membrane potential, mitochondrial permeability transition pore opening, cytochrome C efflux to the cytosol, and apoptosis were subsequently evaluated in the different treatment groups via qRT-PCR, western blotting, and immunofluorescence assays.
UNASSIGNED: DEX intervention increased the translocation of GRs into the mitochondria, while reducing the expression of the mitochondrial gene MT-CO1 and the activity of mitochondrial respiratory chain complex IV in macrophages. In addition, DEX administration increased mtROS levels, mitochondrial permeability transition pore opening, and mitochondrial cytochrome C release in macrophages, which promoted their apoptosis. We found that Tubastatin-A inhibited mitochondrial GR translocation and reversed the DEX-induced increase in GR levels within the mitochondria. Furthermore, Tubastatin-A mitigated various mitochondrial changes induced by DEX, including reducing the efflux of mitochondrial cytochrome C and inhibiting macrophage apoptosis. Similarly, MitoQ exerted its effects on macrophage apoptosis by reducing mtROS levels through the mitochondrial pathway.
UNASSIGNED: The DEX-mediated translocation of GR into mitochondria disrupts the mitochondrial function of macrophages, which induces their apoptosis. By inhibiting mitochondrial translocation of GR and reducing mtROS levels, Tubastatin-A and MitoQ can effectively attenuate macrophage apoptosis, which has clinical implications for reducing the notable side effects associated with glucocorticoid use.